An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.

BACKGROUND Cell-mediated immune responses can be down-regulated by induction of apoptosis of immunoreactive lymphocytes. In the present study, we have tested the feasibility of a strategy for immunosuppression by the selective induction of apoptosis in activated, interleukin (IL)-2 receptor-positive lymphocytes, using a triple IL-2-IgG-FasL fusion protein. The IL-2-IgG-FasL fusion protein combines IL-2 for the selection of activated T cells, with the extracellular domain of the FasL molecule for inducing T-cell apoptosis. These components were separated by the Fc part of IgG1 serving as a spacer as well as for half-life prolongation. METHODS The gene for the chimeric protein was created by fusing DNA sequences encoding for the three functional components: human IL-2, the Fc part of human IgG1, and the extracellular domain of murine FasL. When the fusion gene was expressed in murine J558L cells, we obtained soluble dimeric immunoglobulin-like proteins in the supernatant. After analyzing the function of the IL-2 and FasL portions individually in vitro, a delayed-type hypersensitivity (DTH) reaction to sheep red blood cells as model for cell-mediated immune responses was investigated to evaluate the IL-2-IgG-FasL-mediated immunosuppression in vivo. RESULTS In vitro, the IL-2-IgG-FasL fusion protein supported IL-2-dependent proliferation of Fas-resistant CTLL-2 cells, whereas concanavalin A-T blasts were induced to undergo apoptosis by the FasL portion. In vivo, this fusion protein potently inhibited a murine DTH. This was associated with an increased rate of apoptosis in activated lymphocytes in the spleen, even at very low doses of the fusion protein. Furthermore, a second antigen challenge 10 days after IL-2-IgG-FasL treatment still failed to elicit a DTH response. CONCLUSION The abrogation of a standard T cell-dependent immune response in vivo demonstrates that IL-2-IgG-FasL can be successfully exploited to trigger the death of deleterious T cells, presenting a potentially useful strategy in the management of autoimmune diseases and allotransplant rejections.

[1]  M. Dorf,et al.  Delayed-type hypersensitivity. , 2001, Current protocols in immunology.

[2]  I. Bowen.  Techniques in Apoptosis , 2000 .

[3]  H. von Bernuth,et al.  Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection. , 1998, Cancer research.

[4]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[5]  R. Paus,et al.  Interleukin-15 protects from lethal apoptosis in vivo , 1997, Nature Medicine.

[6]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[7]  R. Paus,et al.  Differential regulation of human T lymphoblast functions by IL-2 and IL-15. , 1997, Cytokine.

[8]  F. Alt,et al.  Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. , 1997, Journal of immunology.

[9]  A. Ashkenazi,et al.  Immunoadhesins as research tools and therapeutic agents. , 1997, Current opinion in immunology.

[10]  A. Abbas,et al.  Die and Let Live: Eliminating Dangerous Lymphocytes , 1996, Cell.

[11]  T. Pohl,et al.  Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. , 1996, The Journal of clinical investigation.

[12]  S. Yonehara,et al.  Normal clonal expansion but impaired Fasmediated cell death and anergy induction in interleukin‐2‐deficient mice , 1995, European journal of immunology.

[13]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[14]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[15]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[16]  A. Lanzavecchia.  Identifying strategies for immune intervention. , 1993, Science.

[17]  T. Blankenstein,et al.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Tanaka,et al.  Cloning of the gamma chain of the human IL-2 receptor. , 1992, Science.

[19]  M. Lenardo.  lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[20]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[21]  S. Morrison,et al.  Immunoglobulin gene expression in transformed lymphoid cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.

[23]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[24]  E. Coligan.  Current protocols in immunology , 1991 .

[25]  F. Seiler,et al.  New Immunosuppressive Drugs , 1991 .